SCRI Tissue Testing Registry

Multiple Myeloma Clinical Trial

Official title:

SCRI Tissue Testing Registry

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00965861
• Other study ID #: SCRI MISC 39
• Status: Terminated
• Phase: N/A
• First received: August 24, 2009
• Last updated: August 27, 2013
• Start date: May 2010
• Est. completion date: February 2013

Study information

• Verified date: August 2013
• Source: SCRI Development Innovations, LLC
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

Sarah Cannon Research Institute (SCRI) is committed to improvement and excellence in clinical research and correlative science. To this end, the SCRI Oncology Research Consortium will collect written consent from patients allowing the use of their tumor tissue sample(s) for testing/analysis at a future date. Future testing may include assays for newly identified markers of potential prognostic and/or therapeutic value. These markers may be specific to an individual cancer type, or they may be present more generally in cancer and/or other conditions.

Description:

Sarah Cannon Research Institute (SCRI) is committed to improvement and excellence in clinical research and correlative science. To this end, the SCRI Oncology Research Consortium will collect written consent from patients allowing the use of their tumor tissue sample(s) for testing/analysis at a future date. Future testing may include assays for newly identified markers of potential prognostic and/or therapeutic value. These markers may be specific to an individual cancer type, or they may be present more generally in cancer and/or other conditions.

This study will consist of a registry of patients who have agreed to allow their tissue sample(s) (even those taken prior to their participation in an SCRI-sponsored trial) to be used by the SCRI Oncology Research Consortium at some point in the future for testing and analysis of expression analysis and/or analysis of tumor markers. The registry will be contained in an electronic database, and will be sorted by disease indication. (Note: Patients will not be asked to return at a future date and have tissue samples collected; rather, SCRI will have the authorization to obtain pre-existing samples).

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 20
• Est. completion date: February 2013
• Est. primary completion date: February 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients must be >= 18 years of age.

• Patients must be able to provide written informed consent.

Exclusion Criteria:

Study Design

Observational Model: Cohort

Related Conditions & MeSH terms

• Lymphoma
• Melanoma
• Multiple Myeloma
• Myelodysplastic Syndrome
• Myelodysplastic Syndromes
• Neoplasms, Plasma Cell
• Preleukemia

Intervention

Other:
• Tissue Registry Study
If a patient consents to allowing the use of their tumor tissue sample(s) for testing/analysis at a future date, their name and information will be stored electronically in a registry that will be managed by SCRI. SCRI may then use the information contained in this registry (such as disease indication, demographic information, etc.) at any time in the future to select tissue samples on which to perform testing/analyses.

Locations

Country	Name	City	State
United States	Tennessee Oncology, PLLC	Nashville	Tennessee

Sponsors (1)

Lead Sponsor	Collaborator
SCRI Development Innovations, LLC

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To establish an electronic registry to store information from patients who have provided their consent allowing use of their tissue sample(s) for future testing.		120 months	No
Primary	To perform testing on the tissue samples to learn more about specific types of cancer and/or other diseases		120 months	No